Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms
- 29 January 2013
- journal article
- research article
- Published by Springer Nature in Purinergic Signalling
- Vol. 9 (3) , 351-365
Abstract
The effects of standard adenosine receptor (AR) agonists and antagonists on the proliferation of human T lymphocytes, unstimulated and phytohemagglutinin-stimulated human peripheral blood lymphocytes (PBL), and Jurkat T cells were investigated. Real-time PCR measurements confirmed the presence of all four AR subtypes on the investigated cells, although at different expression levels. A2A ARs were predominantly expressed in PBL and further upregulated upon stimulation, while malignant Jurkat T cells showed high expression levels of A1, A2A, and A2B ARs. Cell proliferation was measured by [3H]-thymidine incorporation assays. Several ligands, including the subtype-selective agonists CPA (A1), BAY60-6583 (A2B), and IB-MECA (A3), and the antagonists PSB-36 (A1), MSX-2 (A2A), and PSB-10 (A3) significantly inhibited cell proliferation at micromolar concentrations, which were about three orders of magnitude higher than their AR affinities. In contrast, further investigated AR ligands, including the agonists NECA (nonselective) and CGS21680 (A2A), and the antagonists preladenant (SCH-420814, A2A), PSB-1115 (A2B), and PSB-603 (A2B) showed no or only minor effects on lymphocyte proliferation. The anti-proliferative effects of the AR agonists could not be blocked by the corresponding antagonists. The non-selective AR antagonist caffeine stimulated phytohemagglutinin-activated PBL with an EC50 value of 104 μM. This is the first study to compare a complete set of commonly used AR ligands for all subtypes on lymphocyte proliferation. Our results strongly suggest that these compounds induce an inhibition of lymphocyte proliferation and cell death through AR-independent mechanisms.Keywords
This publication has 50 references indexed in Scilit:
- A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune EncephalomyelitisThe Journal of Immunology, 2012
- 2′,3′-cAMP, 3′-AMP, and 2′-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2BreceptorsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Putative role of the adenosine A3 receptor in the antiproliferative action of N 6-(2-isopentenyl)adenosinePurinergic Signalling, 2011
- 2′-AMP and 3′-AMP Inhibit Proliferation of Preglomerular Vascular Smooth Muscle Cells and Glomerular Mesangial Cells via A2B ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Recent developments in adenosine receptor ligands and their potential as novel drugsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An UpdatePharmacological Reviews, 2011
- Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell BiologyThe Journal of Immunology, 2010
- Adenosine A 2A receptor activation protects CD4 + T lymphocytes against activation‐induced cell deathThe FASEB Journal, 2010
- In vitroinduction of T cells that are resistant to A2adenosine receptor‐mediated immunosuppressionBritish Journal of Pharmacology, 2009
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001